CA2477726A1 - Utilisation d'inhibiteurs de tyrosine kinase pour traiter des troubles lies a l'utilisation de substances - Google Patents

Utilisation d'inhibiteurs de tyrosine kinase pour traiter des troubles lies a l'utilisation de substances Download PDF

Info

Publication number
CA2477726A1
CA2477726A1 CA002477726A CA2477726A CA2477726A1 CA 2477726 A1 CA2477726 A1 CA 2477726A1 CA 002477726 A CA002477726 A CA 002477726A CA 2477726 A CA2477726 A CA 2477726A CA 2477726 A1 CA2477726 A1 CA 2477726A1
Authority
CA
Canada
Prior art keywords
kit
inhibitor
compounds
activated
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002477726A
Other languages
English (en)
Inventor
Alain Moussy
Jean-Pierre Kinet
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AB Science SA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2477726A1 publication Critical patent/CA2477726A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

L'invention concerne une méthode de traitement de troubles liés à l'utilisation de substances, plus particulièrement la pharmacodépendance, la toxicomanie, l'accoutumance, le syndrome de sevrage et l'overdose, consistant à administrer un composé capable de réduire le nombre des mastocytes chez un humain nécessitant un tel traitement. De tels composés peuvent être choisis parmi les inhibiteurs de tyrosine kinase et plus particulièrement parmi des inhibiteurs c-kit puissants, sélectifs et non toxiques. Cet inhibiteur est, de préférence, incapable de favoriser la mort de cellules dépendantes d'IL-3 cultivées en présence d'IL-3.
CA002477726A 2002-02-27 2003-02-26 Utilisation d'inhibiteurs de tyrosine kinase pour traiter des troubles lies a l'utilisation de substances Abandoned CA2477726A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35965102P 2002-02-27 2002-02-27
US60/359,651 2002-02-27
PCT/IB2003/001071 WO2003072106A2 (fr) 2002-02-27 2003-02-26 Utilisation d'inhibiteurs de tyrosine kinase pour traiter des troubles lies a l'utilisation de substances

Publications (1)

Publication Number Publication Date
CA2477726A1 true CA2477726A1 (fr) 2003-09-04

Family

ID=27766119

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002477726A Abandoned CA2477726A1 (fr) 2002-02-27 2003-02-26 Utilisation d'inhibiteurs de tyrosine kinase pour traiter des troubles lies a l'utilisation de substances

Country Status (9)

Country Link
US (1) US20050203098A1 (fr)
EP (1) EP1490067B1 (fr)
JP (1) JP2005530696A (fr)
AT (1) ATE408407T1 (fr)
AU (1) AU2003209933A1 (fr)
CA (1) CA2477726A1 (fr)
DE (1) DE60323613D1 (fr)
ES (1) ES2314223T3 (fr)
WO (1) WO2003072106A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8329216B2 (en) 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CN1551770A (zh) 2001-07-06 2004-12-01 ������ҩ�����޹�˾ 羟***酮控释制剂
CA2542909C (fr) 2003-10-23 2012-07-10 Ab Science Composes de 2-aminoaryloxazole destines au traitement de maladies
US8153792B2 (en) 2007-02-13 2012-04-10 Ab Science Process for the synthesis of 2-aminothiazole compounds as kinase inhibitors
CN105974131B (zh) * 2016-06-16 2017-12-26 武汉大学 c‑Kit作为药物成瘾治疗靶点的应用
US20220079950A1 (en) * 2018-12-31 2022-03-17 The Regents Of The University Of California Therapeutic combinations as antidotes for organophosphate exposure
CN112569238A (zh) * 2019-09-30 2021-03-30 武汉大学 伊马替尼及其衍生物与镇痛药联合用药或复方制剂在治疗疼痛中的应用
CN112575073B (zh) * 2019-09-30 2022-10-04 武汉大学 c-Kit作为成瘾诊断及监测标志物的应用
EP4203942A1 (fr) * 2020-08-28 2023-07-05 Emory University Procédés de gestion des dépendances à la cocaïne ou à d'autres drogues
CN114573591B (zh) * 2022-04-16 2023-04-25 成都施贝康生物医药科技有限公司 一种取代的吡咯并嘧啶化合物及其应用
CN117461602A (zh) * 2023-10-25 2024-01-30 六合熙诚(北京)信息科技有限公司 一种***成瘾动物模型的构建方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW225528B (fr) * 1992-04-03 1994-06-21 Ciba Geigy Ag

Also Published As

Publication number Publication date
WO2003072106A3 (fr) 2004-04-22
DE60323613D1 (de) 2008-10-30
ATE408407T1 (de) 2008-10-15
WO2003072106A2 (fr) 2003-09-04
AU2003209933A1 (en) 2003-09-09
JP2005530696A (ja) 2005-10-13
ES2314223T3 (es) 2009-03-16
EP1490067A2 (fr) 2004-12-29
WO2003072106A8 (fr) 2004-10-07
EP1490067B1 (fr) 2008-09-17
US20050203098A1 (en) 2005-09-15

Similar Documents

Publication Publication Date Title
US20090082360A1 (en) Use of tyrosine kinase inhibitors for treating CNS disorders
Ye et al. Protein kinase CK2 increases glutamatergic input in the hypothalamus and sympathetic vasomotor tone in hypertension
US7741335B2 (en) Use of tyrosine kinase inhibitors for treating inflammatory diseases
WO2003002114A2 (fr) Utilisation d'inhibiteurs de c-kit puissants, selectifs et non toxiques dans le traitement de la mastocytose
WO2003024386A2 (fr) Utilisation d'inhibiteurs c-kit puissants, selectifs et non toxiques pour le traitement de la cystopathie interstitielle sous-muqueuse
CA2452200A1 (fr) Technique d'identification de composes ayant un effet de depletion specifiquement sur des mastocytes
CA2477726A1 (fr) Utilisation d'inhibiteurs de tyrosine kinase pour traiter des troubles lies a l'utilisation de substances
WO2003003006A2 (fr) Nouveaux inhibiteurs selectifs puissants et non toxiques de c-kit
CA2452167A1 (fr) Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de la sclerose en plaques
CA2452390A1 (fr) Utilisation d'inhibiteurs de la tyrosine kinase dans le traitement de la perte osseuse
CA2452371A1 (fr) Utilisation d'inhibiteurs de tyrosine kinase dans le traitement de maladies allergiques
CA2452366A1 (fr) Utilisation d'inhibiteurs de materiel c, puissants, selectifs et non toxiques pour traiter l'angiogenese tumorale
US20050089838A1 (en) Method for identifying compounds that specifically deplete mast cells
AU2002324265A1 (en) Use of tyrosine kinase inhibitors for treating inflammatory diseases
AU2002321734A1 (en) Use of tyrosine kinase inhibitors for treating bone loss
AU2002330716A1 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
AU2002324264A1 (en) Use of tyrosine kinase inhibitors for treating multiple sclerosis (MS)
AU2002321738A1 (en) New potent, selective and non toxic C-kit inhibitors
AU2002321739A1 (en) Use of tyrosine kinase inhibitions for treating allergic diseases
AU2002321740A1 (en) Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis

Legal Events

Date Code Title Description
FZDE Discontinued